EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study

Panu Wetwittayakhlang, Khaled Karkout, Arti Wongcha-Um, Paraskevi Tselekouni, Reem Al-Jabri, Waqqas Afif, Gary Wild, Alain Bitton, Talat Bessissow, Peter L Lakatos

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2023.06.022 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Panu Wetwittayakhlang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; Gastroenterology and Hepatology Unit, Div…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We aimed to evaluate clinical efficacy, biomarker activity, therapeutic drug monitoring (TDM), adverse events (AEs), and nocebo effect in inflammatory bowel disease (IBD) patients who underwent non-medical biosimilar switching. METHODS: A prospective observational study of consecutive IBD patients who underwent biosimilar switch. Disease activity, biomarkers, TDM, and AEs, including the nocebo effect were captured 8 weeks before switch, at the time of switch (baseline),12 and 24 weeks after the switch. RESULTS: 210 patients were included [81.4% had Crohn's disease (CD), the median age at inclusion: 42 years (IQR 29-61)]. There was no significant difference in the rates of clinical remission at week 8 before switch, baseline, week12, and 24 after switch: 89.0%,93.4%,86.3%,and 90.8%,p = 0.129. The biomarker remission rates were not significantly different; CRP:81.3%,74.7%,81.2%,73.0%,p = 0.343; fecal calprotectin: 78.3%,74.5%,71.7%,76.3%,p = 0.829. The rates of maintaining therapeutic levels (84.7%,83.9%,83.0%,85.3%,p = 0.597) and prevalence of positive anti-drug antibodies remained unchanged. Drug persistence at 12 week of switch was 97.1%, regardless of disease phenotype and originator. The nocebo effect was observed in 13.3%. The discontinuation rate was 4.8%. CONCLUSION: Despite a significant number of early nocebo complaints within the first 6 months after the biosimilar switch, no significant changes were found in clinical efficacy, biomarkers, therapeutic drug level, or anti-drug antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsInflammatory Bowel DiseasesHumansAdultMiddle AgedInfliximabNocebo EffectGastrointestinal AgentsAntibodies, MonoclonalDrug SubstitutionTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

Anti-tumor necrosis factorBiosimilarEfficacyInflammatory bowel diseaseNocebo

Substanzen

InfliximabBiosimilar PharmaceuticalsGastrointestinal AgentsAntibodies, MonoclonalBiomarkers

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla Uni…
  • Division of Internal Medicine McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada.
  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada.
  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; Department of Internal Medicine and Oncology, Semmelweis University, Budapest H-1085, Hungary. Electronic addre…

Zitieren

APA

Wetwittayakhlang, P., Karkout, K., Wongcha-Um, A., Tselekouni, P., Al-Jabri, R., Afif, W., Wild, G., Bitton, A., Bessissow, T., & Lakatos, P. L. (2024). Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.06.022

Vancouver

Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, et al. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.06.022

BibTeX
@article{Wetwittayakhlang2024,
  author = {Wetwittayakhlang, Panu and Karkout, Khaled and Wongcha-Um, Arti and Tselekouni, Paraskevi and Al-Jabri, Reem and Afif, Waqqas and Wild, Gary and Bitton, Alain and Bessissow, Talat and Lakatos, Peter L},
  title = {Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2023.06.022}
}
Kostenlos starten →